Skip to main content

Table 1 Immunisation schedule

From: Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model

Group Animal numbers Vaccine Schedule (weeks) Challenge virus
A A71, A75, A76, A78 W61D rgp120+ AS02A 1, 4, 12, 20, 28, 36, 44, 86 SHIVsbga
B A72, A73, A74, A77 W61D rgp120+ AS02A 1, 4, 12, 20, 28, 36, 44, 92 SHIVSF33b
C B234-B237 AS02A   SHIVsbgc
D B238-B241 AS02A   SHIVSF33d
E C37-C40 Serum transfer   SHIVsbge
F C41-C44 None   SHIVsbgf
G G19; G21 W61D rgp120+ AS02A 1, 4, 8 None
  1. a = 10 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
  2. b = 50 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
  3. c = 10MID50 challenge dose contemporaneous with group A.
  4. d = 50MID50 challenge dose contemporaneous with group B.
  5. e = 50MID50 challenge dose given 24 hours following serum transfer.
  6. f = 50MID50 contemporaneous with group F.